$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044737 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$21.67M
YoY Change		35.24%
Cost Of Revenue		$1.992M
YoY Change		13.74%
Gross Profit		$19.68M
YoY Change		37.87%
Gross Profit Margin		90.81%
Selling, General & Admin		$18.99M
YoY Change		36.86%
% of Gross Profit		96.51%
Research & Development		$1.360M
YoY Change		37.82%
% of Gross Profit		6.91%
Depreciation & Amortization		$129.6K
YoY Change		11.15%
% of Gross Profit		0.66%
Operating Expenses		$21.60M
YoY Change		42.31%
Operating Profit		-$1.924M
YoY Change		112.21%
Interest Expense		$927.6K
YoY Change		392.62%
% of Operating Profit
Other Income/Expense, Net		-$959.0K
YoY Change		409.32%
Pretax Income		-$2.883M
YoY Change		163.3%
Income Tax
% Of Pretax Income
Net Earnings		-$2.858M
YoY Change		169.51%
Net Earnings / Revenue		-13.19%
Basic Earnings Per Share		-$0.34
Diluted Earnings Per Share		-$0.34
COMMON SHARES
Basic Shares Outstanding	8.741M shares	8.747M shares
Diluted Shares Outstanding		8.517M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$16.28M
YoY Change		160.85%
Cash & Equivalents		$16.28M
Short-Term Investments
Other Short-Term Assets		$429.4K
YoY Change		-30.74%
Inventory		$3.008M
Prepaid Expenses
Receivables		$11.11M
Other Receivables		$1.079M
Total Short-Term Assets		$31.91M
YoY Change		64.69%
LONG-TERM ASSETS
Property, Plant & Equipment		$995.8K
YoY Change		-24.96%
Goodwill		$3.602M
YoY Change		0.0%
Intangibles		$42.03M
YoY Change		-8.62%
Long-Term Investments		$8.321M
YoY Change		170.18%
Other Assets
YoY Change
Total Long-Term Assets		$56.64M
YoY Change		0.96%
TOTAL ASSETS
Total Short-Term Assets		$31.91M
Total Long-Term Assets		$56.64M
Total Assets		$88.55M
YoY Change		17.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.452M
YoY Change		-27.4%
Accrued Expenses		$10.98M
YoY Change		9.92%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$14.34M
YoY Change		8.41%
LONG-TERM LIABILITIES
Long-Term Debt		$30.08M
YoY Change		217.99%
Other Long-Term Liabilities		$2.006M
YoY Change		-58.83%
Total Long-Term Liabilities		$34.75M
YoY Change		91.48%
TOTAL LIABILITIES
Total Short-Term Liabilities		$14.34M
Total Long-Term Liabilities		$34.75M
Total Liabilities		$49.09M
YoY Change		56.46%
SHAREHOLDERS EQUITY
Retained Earnings		-$36.25M
YoY Change		30.38%
Common Stock		$76.03M
YoY Change		5.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$39.78M
YoY Change
Total Liabilities & Shareholders Equity		$88.55M
YoY Change		17.32%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$2.858M
YoY Change		169.51%
Depreciation, Depletion And Amortization		$129.6K
YoY Change		11.15%
Cash From Operating Activities		$2.050M
YoY Change		93.44%
INVESTING ACTIVITIES
Capital Expenditures		$9.100K
YoY Change		-94.65%
Acquisitions
YoY Change
Other Investing Activities		-$6.348M
YoY Change		-36.14%
Cash From Investing Activities		-$6.357M
YoY Change		-37.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		14.43M
YoY Change		56.37%
NET CHANGE
Cash From Operating Activities		2.050M
Cash From Investing Activities		-6.357M
Cash From Financing Activities		14.43M
Net Change In Cash		10.13M
YoY Change		5526.01%
FREE CASH FLOW
Cash From Operating Activities		$2.050M
Capital Expenditures		$9.100K
Free Cash Flow		$2.041M
YoY Change		129.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Cost Of Revenue CostOfRevenue	6064524	usd
	us-gaap	Gross Profit GrossProfit	54476341	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000714256
CY2023Q4	us-gaap	Inventory Net InventoryNet	4717533	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16024948	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	1991987	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1751349	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	19679612	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18993255	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13877879	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1359530	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	986454	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1103854	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	997674	usd
CY2024Q3	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	-147000	usd
CY2023Q3	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	681753	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	21603639	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	15180254	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1924027	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-906655	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	927577	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	188294	usd
CY2024Q3	SMTI	Royalty Receivable RoyaltyReceivable		usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	SMTI	Backend Fee BackendFee		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1		usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q3	SMTI	Executive Separation Costs ExecutiveSeparationCosts		usd
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	SMTI	Executive Separation Costs ExecutiveSeparationCosts		usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39678
	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
	dei	City Area Code CityAreaCode	(817)
	dei	Local Phone Number LocalPhoneNumber	529-2300
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	SMTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8741161	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16277189	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5147216	usd
CY2023Q4	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	3008349	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1079411	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	429428	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	608411	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	31908408	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	19005869	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	42029142	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44926061	usd
CY2024Q3	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	8321412	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1688963	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1995204	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	995770	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	56637068	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	54865280	usd
CY2024Q3	us-gaap	Assets Assets	88545476	usd
CY2023Q4	us-gaap	Assets Assets	73871149	usd
CY2024Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	8256801	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7676770	usd
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2285374	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2047678	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1906550	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1100000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	439129	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	361185	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14339827	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13767877	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30076715	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2006000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2723001	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1407164	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1737445	usd
CY2024Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	1261495	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1941686	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34751374	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15515255	usd
CY2024Q3	us-gaap	Liabilities Liabilities	49091201	usd
CY2023Q4	us-gaap	Liabilities Liabilities	29283132	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8743174	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8743174	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8535239	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8535239	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	8743	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8535	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	76021528	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72860556	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36246405	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28036814	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	39783866	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	44832277	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-329591	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-244260	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39454275	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88545476	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73871149	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21671599	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60367060	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47300029	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5890719	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	14273599	usd
	us-gaap	Gross Profit GrossProfit	41235505	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	54143122	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40658424	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3291479	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3480906	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3314781	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2580243	usd
	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	-67549	usd
	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	1494910	usd
	us-gaap	Operating Expenses OperatingExpenses	60816931	usd
	us-gaap	Operating Expenses OperatingExpenses	45224663	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6340590	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3989158	usd
	us-gaap	Interest Expense InterestExpense	1839259	usd
	us-gaap	Interest Expense InterestExpense	188300	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-959025	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188294	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1870707	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188300	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2883052	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
	us-gaap	Profit Loss ProfitLoss	-8211297	usd
	us-gaap	Profit Loss ProfitLoss	-4177458	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25284	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34579	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-85331	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-111455	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2857768	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1060370	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8125966	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4066003	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8517381	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8517381	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8332341	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8332341	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8468394	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8468394	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8244503	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8244503	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	597305	usd
CY2023Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-655942	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1033761	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1127332	usd
CY2023Q2	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	224576	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1866180	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40964498	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	857526	usd
CY2023Q3	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	281070	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3089645	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44097790	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	803386	usd
CY2024Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-580794	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1799043	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43011566	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1411545	usd
CY2024Q2	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	508086	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-3529202	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41401995	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41401995	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1025431	usd
CY2024Q3	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-15099	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-75000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2883052	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39454275	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39454275	usd
	us-gaap	Profit Loss ProfitLoss	-8211297	usd
	us-gaap	Profit Loss ProfitLoss	-4177458	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3314781	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2580243	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	230930	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	214061	usd
	us-gaap	Inventory Write Down InventoryWriteDown	356261	usd
	us-gaap	Inventory Write Down InventoryWriteDown	222691	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3240362	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2582163	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	306240	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	243988	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
	SMTI	Backend Fee BackendFee	219689	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	424067	usd
	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities	166595	usd
	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities	39699	usd
	SMTI	Amortization And Writeoff Of Debt Issuance Costs AmortizationAndWriteoffOfDebtIssuanceCosts	150219	usd
	SMTI	Amortization And Writeoff Of Debt Issuance Costs AmortizationAndWriteoffOfDebtIssuanceCosts	2055	usd
	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	-67549	usd
	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	1494910	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2777243	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	794344	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	35009	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-87516	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1352923	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1664714	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-178963	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-482921	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-622719	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	547186	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	72806	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	30711	usd
	SMTI	Increase Decrease In Accrued Royalties And Expenses IncreaseDecreaseInAccruedRoyaltiesAndExpenses	249910	usd
	SMTI	Increase Decrease In Accrued Royalties And Expenses IncreaseDecreaseInAccruedRoyaltiesAndExpenses	557295	usd
	SMTI	Increase Decrease In Accrued Bonuses And Commissions IncreaseDecreaseInAccruedBonusesAndCommissions	580031	usd
	SMTI	Increase Decrease In Accrued Bonuses And Commissions IncreaseDecreaseInAccruedBonusesAndCommissions	-1673629	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-252337	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-182498	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-955831	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2397024	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133676	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	210970	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	650	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	5268582	usd
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	1079391	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9942750	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6481649	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10153070	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	29339260	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	9688341	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	9750000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	-75000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1033761	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-87807	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-150296	usd
	SMTI	Cash Payment Of Finance And Earnout Liabilities CashPaymentOfFinanceAndEarnoutLiabilities	859000	usd
	SMTI	Cash Payment Of Finance And Earnout Liabilities CashPaymentOfFinanceAndEarnoutLiabilities	744795	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18567453	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9827011	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11129973	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2723083	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5147216	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16277189	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6235912	usd
	us-gaap	Interest Paid Net InterestPaidNet	948759	usd
	us-gaap	Interest Paid Net InterestPaidNet	146546	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1531773	usd
	us-gaap	Stock Issued1 StockIssued1	3089645	usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	3759642	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zr5aXZB0wGH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82E_z6M4Y9mqeoe5">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies are designed to achieve the Company’s goal of providing better clinical outcomes at a lower overall cost for patients, regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2020, the Company formed a subsidiary, United Wound and Skin Solutions, LLC (formerly known as “WounDerm”), to hold certain investments and operations in wound and skincare virtual consult services. In 2023, WounDerm was renamed to, and is now doing business as, “Tissue Health Plus” (“THP”). THP is continuing its mission to simplify skin health, starting with wound care through a refined business plan. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and value-based care (“VBC”) primary care companies, with Medicare Advantage payers as the initial target market for this program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As further discussed in Note 12, the Company historically managed its business on the basis of <span id="xdx_90E_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20240101__20240930_zXTVzLo04YFh" title="Number of operating segment"><span id="xdx_907_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20240930_zyWW9XsRPIce" title="Number of reportable segment">one</span></span> operating and reportable segment. During the second quarter of 2024, the Company changed its reportable segments to reflect the manner in which the business is managed. Based on the growing importance of the value-based wound care program to the Company’s future outlook and how the Company’s chief operating decision maker, the Chief Executive Officer, reviews operating results and makes decisions about resource allocation, the Company now has <span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240930_zc7OwkQFFXte" title="Number of reportable segment">two</span> reportable segments: Sanara Surgical and THP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sanara Surgical </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical’s soft tissue repair products include, among other products, the Company’s lead product, CellerateRX Surgical Activated Collagen (“CellerateRX Surgical”), and BIASURGE Advanced Surgical Solution, which is a no-rinse, advanced surgical solution used for wound irrigation. Sanara Surgical’s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products under development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tissue Health Plus </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and VBC primary care companies, with Medicare Advantage payers as the initial target market for this program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THP’s programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community-based care spans a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP’s programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation. Throughout this Quarterly Report on Form 10-Q, unless otherwise indicated, amounts and activity reflect reclassifications related to the Company’s change in reportable segments. The change in reportable segments had no impact on the Company’s previously reported Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows or Consolidated Statements of Shareholders’ Equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	integer
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	integer
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zyx4kPRwJIJ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zaAnl7ung0oc">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21671599	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16024948	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60367060	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47300029	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	75000	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128061	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	230930	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	214061	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	758960	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	528030	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	5010	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	3820	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	96684	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	152701	usd
	us-gaap	Inventory Write Down InventoryWriteDown	356261	usd
	us-gaap	Inventory Write Down InventoryWriteDown	222691	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	466276	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	446917	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2587756	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2454080	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1591986	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1196124	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	995770	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2024Q3	us-gaap	Depreciation Depreciation	129592	usd
CY2023Q3	us-gaap	Depreciation Depreciation	116596	usd
	us-gaap	Depreciation Depreciation	395862	usd
	us-gaap	Depreciation Depreciation	332762	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3823001	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	67549	usd
	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Revaluation Of Earnout Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability	22000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3912550	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q3	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q3	us-gaap	Goodwill Goodwill	3601781	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y6M
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	974262	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	881079	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2918919	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2247482	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	972818	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3891270	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3874015	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3760162	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3726921	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3726921	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	22077035	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42029142	usd
CY2024Q3	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2023Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2024Q3	us-gaap	Investments Investments	8321412	usd
CY2023Q4	us-gaap	Investments Investments	3084278	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1688963	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1846293	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	121126	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	110693	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	416394	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	295268	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	362491	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	264291	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	142525	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	532053	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	379529	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	297947	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	295689	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	300158	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	303892	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2251793	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	405500	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1846293	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	439129	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1407164	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0766	pure
CY2024Q3	SMTI	Minimum Cash Balance Value MinimumCashBalanceValue	3000000.0	usd
	SMTI	Annual Minimum Revenue Year One AnnualMinimumRevenueYearOne	60000000.0	usd
	SMTI	Annual Minimum Revenue Year Two AnnualMinimumRevenueYearTwo	75000000.0	usd
	SMTI	Annual Minimum Revenue Year Three AnnualMinimumRevenueYearThree	85000000.0	usd
	SMTI	Annual Minimum Revenue Year Four AnnualMinimumRevenueYearFour	95000000.0	usd
	SMTI	Annual Minimum Revenue Year Five AnnualMinimumRevenueYearFive	105000000.0	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	31143756	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1067041	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56520	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	30076715	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	9693480	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30076715	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2024Q3	SMTI	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	31143756	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	31143756	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1067041	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56520	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	150219	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2055	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.22
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	62879	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.05
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	31013	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.57
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	547530.6	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	31013	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.57
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	547530.6	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2023Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2024Q3	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2024Q3	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2024Q3	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P6Y
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	integer
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	integer
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21671599	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16024948	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	19679612	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	14273599	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18993255	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13877879	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1359530	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	986454	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1103854	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	997674	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	927577	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	188294	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2883052	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
CY2024Q3	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	841961	usd
CY2023Q3	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	266792	usd
CY2024Q3	us-gaap	Assets Assets	88545476	usd
CY2023Q3	us-gaap	Assets Assets	73871149	usd
CY2024Q3	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	9096	usd
CY2023Q3	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	170320	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60367060	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47300029	usd
	us-gaap	Gross Profit GrossProfit	54476341	usd
	us-gaap	Gross Profit GrossProfit	41235505	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	54143122	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40658424	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3291479	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3480906	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3314781	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2580243	usd
	us-gaap	Interest Expense InterestExpense	1839259	usd
	us-gaap	Interest Expense InterestExpense	188300	usd
	us-gaap	Profit Loss ProfitLoss	-8211297	usd
	us-gaap	Profit Loss ProfitLoss	-4177458	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	1745566	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	-321662	usd
CY2024Q3	us-gaap	Assets Assets	88545476	usd
CY2023Q3	us-gaap	Assets Assets	73871149	usd
	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	133676	usd
	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	210970	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2883052	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1094949	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	927577	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	188294	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1103854	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	997674	usd
CY2024Q3	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1025430	usd
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	857526	usd
CY2024Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	147000	usd
CY2023Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-681753	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
CY2024Q3	SMTI	Executive Separation Costs ExecutiveSeparationCosts	59685	usd
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	430019	usd
CY2024Q3	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	841961	usd
CY2023Q3	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	266792	usd
	us-gaap	Profit Loss ProfitLoss	-8211297	usd
	us-gaap	Profit Loss ProfitLoss	-4177458	usd
	us-gaap	Interest Expense InterestExpense	1839259	usd
	us-gaap	Interest Expense InterestExpense	188300	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3314781	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2580243	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	2911567	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	2582163	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	67549	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1494910	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-31448	usd
	SMTI	Executive Separation Costs ExecutiveSeparationCosts	964466	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	827793	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	1745566	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	-321662	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328795	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	SMTI	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024Q3	SMTI	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-044737-index-headers.html	Edgar Link	pending
0001493152-24-044737-index.html	Edgar Link	pending
0001493152-24-044737.txt	Edgar Link	pending
0001493152-24-044737-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20240930.xsd	Edgar Link	pending
smti-20240930_def.xml	Edgar Link	unprocessable
smti-20240930_lab.xml	Edgar Link	unprocessable
smti-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
smti-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2024 Q4 Form 10-Q Financial Statement

#000149315224044737 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2024 Q4 Form 10-Q Financial Statement

#000149315224044737 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti